A

Arvinas
D

ARVN

8.71000
USD
-0.05
(-0.57%)
Market Closed
Volume
29,199
EPS
-1
Div Yield
-
P/E
34
Market Cap
569,513,724
Overview
Related Instruments
ABBV
ABBV
D
ABBVIE
255.01
4.03(1.61%)
255.00-0.01(-0.00%)
AZN
AZN
D
AstraZeneca PLC
159.616
2.696(1.72%)
160.270+0.654(+0.41%)
BMY
BMY
D
Bristol-Myers Squibb Co
63.750
-0.650(-1.01%)
BNTX
BNTX
D
BioNTech SE American Depositary Share
96.375
-1.795(-1.83%)
96.400+0.025(+0.03%)
GSK
GSK
D
GSK plc
48.130
-0.510(-1.05%)
JNJ
JNJ
D
Johnson & Johnson
266.37
-0.84(-0.31%)
266.33-0.04(-0.02%)
MRNA
MRNA
D
Moderna
136.570
0.900(0.66%)
135.520-1.050(-0.77%)
NVS
NVS
D
Novartis AG
137.480
-0.020(-0.01%)
PFE
PFE
D
Pfizer
27.640
-0.145(-0.52%)
27.630-0.010(-0.04%)
More
Articles
ARVN article featured image

What Is the DAX and How to Invest in It?

Learn what the DAX index is, how it works, which companies it includes, and how you can invest or trade it. A practical guide for retail investors and traders.

2 weeks ago
Trading Beginners
More

Title: Arvinas

Sector: Healthcare
Industry: Biotechnology
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to targetcertain harmful proteins causing oncology and neurology-related diseases.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.